Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm
Hematology/Oncology Clinics of North America, ISSN: 0889-8588, Vol: 34, Issue: 3, Page: 589-600
2020
- 17Citations
- 16Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes17
- 17
- CrossRef15
- Captures16
- Readers16
- 16
Review Description
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan hematologic malignancy with poor outcomes. Tagraxofusp (SL-401) was the first drug approved specifically for patients with BPDCN, in 2018. Additional therapeutic strategies are still needed to improve survival and minimize treatment-related toxicity. This article outlines novel targeted approaches that are in preclinical or clinical development for BPDCN. Although there is no known targetable genetic abnormality that defines BPDCN, data from functional testing of primary tumors, gene expression analyses, and adaptation of targeted drug approaches from other cancers to BPDCNs harboring specific mutations have nominated several promising strategies.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0889858820300186; http://dx.doi.org/10.1016/j.hoc.2020.01.007; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85081755272&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/32336422; https://linkinghub.elsevier.com/retrieve/pii/S0889858820300186; https://dx.doi.org/10.1016/j.hoc.2020.01.007
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know